Product information and disease descriptionProduct descriptionProduct information
Product comparison
28 evidence topics · 16 sources
Tetrabenazine: indication, boxed warning monitoring, and individualized oral dosing
Deutetrabenazine: indication, boxed warning monitoring, and oral dosing
Valbenazine: indication, boxed warning monitoring, and oral dosing
Approved VMAT2 inhibitors: indirect tolerability comparison of deutetrabenazine and tetrabenazine
“Compared with tetrabenazine, deutetrabenazine was associated with a significantly lower risk of moderate to severe AEs and neuropsychiatric AEs including agitation, akathisia, depression, depression/agitated depression, drowsiness/somnolence, insomnia, and parkinsonism in both adjusted and unadjusted analyses (p < 0.05 for each).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Approved VMAT2 inhibitors: GRADE-based indirect comparison
Symptomatic antichoreic agents: open-label randomized comparison of tetrabenazine, tiapride, and olanzapine
“We conducted a pragmatic, randomized, open-label trial across 11 centers of the French-Speaking Huntington's Network, enrolling 179 patients with Huntington's disease.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Tetrabenazine was most frequently associated with mood disorders and sedation, while olanzapine caused occasional weight gain and mild increases in LDL and total cholesterol.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Route of administration compared with antisense oligonucleotides and gene therapy
HTT lowering targets in other trials: independent commentary
Registered trials of investigational disease-modifying therapies: mechanism, comparator, and design
Delivery routes under investigation: subcutaneous SRP-1005 as an alternative to intrathecal or neurosurgical administration
“SRP-1005 is designed to reduce HTT expression following subcutaneous administration through a transferrin receptor 1 -mediated delivery platform intended to facilitate central nervous system (CNS) penetration.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The programme is noteworthy for its systemic subcutaneous delivery approach, which, if successful, could provide an alternative to intrathecal or neurosurgical administration strategies currently being investigated for HTT-lowering therapies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Votoplam: oral splicing modifier, 24-month extension versus natural history
Votoplam: route and 12-week PIVOT-HD primary endpoint
“PTC518 (also known as votoplam), an orally administered huntingtin mRNA splice modulator.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The study met its primary endpoint, showing dose-dependent reductions in blood HTT protein levels at week 12, along with a favourable safety and tolerability profile across all dose levels and disease stages.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Votoplam: phase 3 INVEST-HD design
“INVEST-HD is a randomised, placebo-controlled, double-blind, phase III interventional study designed to evaluate whether votoplam slows disease progression in participants with early symptomatic HD compared with placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Votoplam, also referred to as HTT227 (and formerly known as PTC518), is an orally administered small-molecule HTT-lowering therapy now being developed by Novartis for HD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Participants are randomised in a 3:2 ratio to oral votoplam or placebo, with a variable double-blind treatment duration of up to 36 months, followed by a safety follow-up visit for participants not entering a separate open-label extension.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The estimated enrolment is 770 participants.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
SKY-0515 in relation to huntingtin-only lowering: independent trials review
“SKY-0515 is designed to reduce both HTT and PMS1 proteins, the latter implicated in somatic CAG repeat expansion, a mechanistic process increasingly recognised as a key driver of neuronal loss in HD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This important phase II/III clinical trial of SKY-0515 will assess whether HTT and PMS1 lowering can offer greater therapeutic benefit than HTT reduction alone in early-stage HD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
SKY-0515: twelve-month data compared with natural history and phase II/III FALCON-HD
“As previously featured in the October 2025 update, 13 Skyhawk Therapeutics has reported new interim data from the ongoing phase I/II study of SKY-0515.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Treated participants demonstrated positive mean changes from baseline in cUHDRS scores over 12 months, compared with an expected decline derived from propensity-weighted analyses of Enroll-HD and TRACK-HD natural-history datasets.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Skyhawk also announced completion of enrolment in the Australia and New Zealand component of the phase II/III FALCON-HD programme (004-ANZ), with 144 participants enrolled ahead of schedule, and expansion of the global FALCON-HD study (NCT07378644) 41 to eight countries.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
External natural-history comparisons across HTT-lowering trials
Tominersen: phase 3 GENERATION HD1 dosing discontinued
Tominersen: GENERATION HD1 design and primary end points
“in which 791 participants with manifest Huntington’s disease were randomly assigned in a 1:1:1 ratio to receive intrathecal tominersen, at a dose of 120 mg every 8 weeks or every 16 weeks, or placebo” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The primary end point was the change from baseline in the score on the composite Unified Huntington’s Disease Rating Scale (cUHDRS) or Total Functional Capacity (TFC) scale at week 101.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Biomarker end points included levels of mutant HTT in CSF, levels of neurofilament light protein (NfL) in CSF, and ventricular volume.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Tominersen: GENERATION HD1 ad hoc week 69 results with the every-16-week regimen
“In the every-16-week tominersen group, the mean changes from baseline in the scores on the cUHDRS and the TFC scale did not differ significantly from those in the placebo group (−0.16 points, adjusted P=0.84; and −0.04, adjusted P=1.00, respectively)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Nonetheless, these results must be interpreted with caution, given the ad hoc nature of the analysis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Tominersen: GENERATION HD1 biomarkers, adverse events, and post hoc subgroup analyses
“The changes in mutant HTT levels in CSF were consistent with dose regimen–dependent decreases and concomitant increases in ventricular volume” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The absence of whole-brain volume loss in the context of ventricular expansion and the absence of a correlation between the change in CSF NfL levels and change in ventricular volume suggest that increases in ventricular volume do not reflect increased atrophy” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A transient increase was seen in CSF NfL levels in the every-8-week tominersen group at week 21; although neuroaxonal damage may be implicated, increased levels of leukocytes and total protein in CSF in some participants suggest an inflammatory component” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“More adverse events occurred in the participants in the every-8-week tominersen group than in those in the placebo group and the every-16-week tominersen group” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The results of post hoc analyses support the hypothesis that younger participants (who have less disease burden) may benefit from tominersen therapy” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“this hypothesis is currently being tested in a phase 2 dose-finding trial (GENERATION HD2; NCT05686551).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Tominersen: GENERATION HD2 discontinued, July 2026
“On 9th July 2026, Roche announced the discontinuation of the GENERATION HD2 (NCT05686551) 22 study of tominersen in people with prodromal and early Huntington's disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“GENERATION HD2 confirms that sustained lowering of mHTT in humans, even if it lowers wild-type as well, and does not target HTT exon 1, is associated with robust NfL lowering - often taken as indicating reduced rates of neuroaxonal damage - but that clinical benefits, if they are to emerge, may take longer than 16 months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Tominersen: phase 2 GENERATION HD2 unblinding anticipated in late 2026, November 2025, superseded in July 2026
“GENERATION HD2 is a phase II, randomised, double-blind, placebo-controlled, dose-finding clinical trial comparing 60 mg tominersen, 100 mg tominersen and placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The clinical trial remains ongoing, and definitive conclusions regarding clinical benefit will only be possible once the data are unblinded and fully analysed. This is anticipated to be late 2026.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
RG6496: allele-selective intrathecal antisense oligonucleotide, POINT-HD terminated
“RG6496 is a selective ASO designed to lower mHTT protein while largely preserving expression of the wild-type protein.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“It is administered intrathecally and achieves allele selectivity by targeting a single nucleotide polymorphism (SNP) present on the expanded huntingtin gene (HTT) allele.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“POINT-HD was terminated following new findings from a longer-term non-clinical study indicating that RG6496 could not be administered chronically with repeated dosing.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pridopidine: phase 3 PROOF-HD and EMA opinion
“The primary and key secondary endpoints, change in total functional capacity (TFC) and composite Unified Huntington's Disease Rating Scale (cUHDRS) score at week 65, were not met in the overall population.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pridopidine: phase III PRECISE-HD in people not receiving antidopaminergic medications
“PRECISE-HD is a randomised, placebo-controlled, double-blind, phase III interventional study evaluating pridopidine 45 mg twice daily in adults with HD who have not used anti-dopaminergic medications for at least six months before screening.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The primary outcome measure is change from baseline to week 52 in cUHDRS score.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Approved AAV gene therapy: Kebilidi indication under accelerated approval
Kebilidi: accelerated approval on a single-arm study compared with an external natural history cohort
Kebilidi: confirmatory evidence required for continued approval
Direct head-to-head comparison of ifezuntirgene inilparvovec with an approved or investigational therapy
No evidence found.